%0 Journal Article
%T Evaluation of Different Glycemic Control Regimens on the Prognosis of Coronary Heart Disease Combined with Type 2 Diabetes
%A Lili Sun
%A Hui Hui
%J World Journal of Cardiovascular Diseases
%P 622-630
%@ 2164-5337
%D 2024
%I Scientific Research Publishing
%R 10.4236/wjcd.2024.1410054
%X <b>Aim:</b> To explore the safety and effectiveness of combining dapagliflozin and metformin with sitagliptin in patients with coronary heart disease and type 2 diabetes whose blood sugar control is below the standard. <b>Method:</b> From January 2022 to January 2023, 100 patients with poorly controlled blood sugar among those hospitalized with type 2 diabetes and coronary heart disease were selected. They were divided into an experimental group of 55 cases (combined with sitagliptin) and a control group of 45 cases (combined with insulin or glimepiride) based on dapagliflozin and metformin and followed up for 1 year. The rates of reaching blood sugar targets, heart function indicators, inflammatory factor results, and major adverse cardiovascular events were compared between the two groups. <b>Results:</b> After treatment, there was no statistical difference between the two groups in the 3-month, 6-month, and 12-month follow-up blood sugar indicators (FPG, 2hPG, HbA1c levels) and heart function indicators (NT-proBNP, LVEF, LVEDD) (P &gt; 0.05). After 12 months of treatment, the levels of IL-6, CRP, and IL-8 in the observation group were lower than those in the control group, with a statistically significant difference (P &lt; 0.05). After 12 months of treatment, the incidence of cardiovascular events was followed up, with the experimental group having a significantly lower rate of cardiac death than the control group (P &lt; 0.05). The difference in other cardiovascular events was not statistically significant (P &gt; 0.05). <b>Conclusion:</b> Combining sitagliptin with dapagliflozin and metformin in patients with coronary heart disease and type 2 diabetes who have poor blood sugar control can effectively manage blood sugar, reduce inflammation levels, and decrease the incidence of cardiac death, making it worthy of clinical application and promotion.
%K Coronary Heart Disease
%K Type 2 Diabetes
%K Sitagliptin
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=136488